Javascript must be enabled to continue!
Relapse Following Electroconvulsive Therapy for Schizophrenia: A Systematic Review and Meta-analysis
View through CrossRef
Abstract
Background
Evidence regarding schizophrenia relapse following acute electroconvulsive therapy (ECT) is sparse compared with that for depression, and we have no clear consensus on relapse proportions. We aimed to provide longitudinal information on schizophrenia relapse following acute ECT.
Study Design
This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies on post-acute ECT relapse and rehospitalization for schizophrenia and related disorders. For the primary outcome, we calculated the post-acute ECT pooled relapse estimates at each timepoint (3, 6, 12, and 24 months post-acute ECT) using a random effects model. For subgroup analyses, we investigated post-acute ECT relapse proportions by the type of maintenance therapy.
Study Results
Among a total of 6413 records, 29 studies (3876 patients) met our inclusion criteria. The risk of bias was consistently low for all included RCTs (4 studies), although it ranged from low to high for observational studies (25 studies). Pooled estimates of relapse proportions among patients with schizophrenia responding to acute ECT were 24% (95% CI: 15-35), 37% (27-47), 41% (34-49), and 55% (40-69) at 3, 6, 12, and 24 months, respectively. When continuation/maintenance ECT was added to antipsychotics post-acute ECT, the 6-month relapse proportion was 20% (11-32).
Conclusion
Relapse occurred mostly within 6 months post-acute ECT for schizophrenia, particularly within the first 3 months. Relapse proportions plateaued after 6 months, although more than half of all patients could be expected to relapse within 2 years. Further high-quality research is needed to optimise post-acute ECT treatment strategies in patients with schizophrenia.
Oxford University Press (OUP)
Title: Relapse Following Electroconvulsive Therapy for Schizophrenia: A Systematic Review and Meta-analysis
Description:
Abstract
Background
Evidence regarding schizophrenia relapse following acute electroconvulsive therapy (ECT) is sparse compared with that for depression, and we have no clear consensus on relapse proportions.
We aimed to provide longitudinal information on schizophrenia relapse following acute ECT.
Study Design
This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies on post-acute ECT relapse and rehospitalization for schizophrenia and related disorders.
For the primary outcome, we calculated the post-acute ECT pooled relapse estimates at each timepoint (3, 6, 12, and 24 months post-acute ECT) using a random effects model.
For subgroup analyses, we investigated post-acute ECT relapse proportions by the type of maintenance therapy.
Study Results
Among a total of 6413 records, 29 studies (3876 patients) met our inclusion criteria.
The risk of bias was consistently low for all included RCTs (4 studies), although it ranged from low to high for observational studies (25 studies).
Pooled estimates of relapse proportions among patients with schizophrenia responding to acute ECT were 24% (95% CI: 15-35), 37% (27-47), 41% (34-49), and 55% (40-69) at 3, 6, 12, and 24 months, respectively.
When continuation/maintenance ECT was added to antipsychotics post-acute ECT, the 6-month relapse proportion was 20% (11-32).
Conclusion
Relapse occurred mostly within 6 months post-acute ECT for schizophrenia, particularly within the first 3 months.
Relapse proportions plateaued after 6 months, although more than half of all patients could be expected to relapse within 2 years.
Further high-quality research is needed to optimise post-acute ECT treatment strategies in patients with schizophrenia.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
The Role of Whole Body STIR MRI in Assessing First Biochemical Relapse in Patients with Myeloma
The Role of Whole Body STIR MRI in Assessing First Biochemical Relapse in Patients with Myeloma
Background: Myeloma remains an incurable disease and most patients will relapse. The optimal timing of salvage initiation remains uncertain although there is a trend to treating ea...
Central nervous system relapse in acute promyelocytic leukemia in the arsenic era: A case series and review of emerging evidence
Central nervous system relapse in acute promyelocytic leukemia in the arsenic era: A case series and review of emerging evidence
Abstract
Background: Acute Promyelocytic Leukemia (APML) is highly curable with all-trans retinoic acid (ATRA) and arsen...
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Abstract
Background
Developments in related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have made two immune systems with inco...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Abstract
The evolutionary model of cancer progression suggests that malignant clones survive initial therapy and acquire new mutations, ultimately resulting in thera...
The cognitive impairments of electroconvulsive therapy
The cognitive impairments of electroconvulsive therapy
IntroductionElectroconvulsive therapy (ECT) is one of the most controversial treatments in medicine, mainly because of its still unknown mechanism of action and uncertainty about c...
Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis
Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis
Abstract
Introduction
Post-transplant maintenance (PTM) therapy with tyrosine kinase inhibitors (TKI...

